|
2025
|
Invention
|
Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric ... |
|
|
Invention
|
Non-linear dosing of mirdametinib.
The present disclosure relates to methods for treating certai... |
|
|
Invention
|
Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-... |
|
2024
|
Invention
|
Mirdametinib treatment. The present disclosure relates to methods for treating certain types of t... |
|
|
Invention
|
Treatments with nirogacestat.
The present disclosure relates to improved methods of treatment wi... |
|
|
Invention
|
Dosage forms of mirdametinib. The present disclosure relates to an oral dosage form, such as a ca... |
|
|
Invention
|
Compositions and treatments with nirogacestat.
The present disclosure relates to compositions an... |
|
|
Invention
|
2-pyrazole anilines and related analogs for inhibiting yap/taz-tead.
The present disclosure rela... |
|
|
Invention
|
Mirdametinib treatment.
The present disclosure relates to a method for treating certain types of... |
|
|
Invention
|
Mirdametinib treatment. max no more than 40 ng/mL, or (iii) both. |
|
|
Invention
|
Tetrahydronapthyridine and related analogs for inhibiting yap/taz-tead.
The present disclosure r... |
|
|
Invention
|
Benzopiperazine and related analogs for inhibiting yap/taz-tead.
The present disclosure relates ... |
|
|
Invention
|
Benzimidazole and related analogs for inhibiting yap/taz-tead.
The present disclosure relates to... |
|
|
Invention
|
Benzimidazole and related analogs for inhibiting yap/taz-tead. The present disclosure relates to ... |
|
|
Invention
|
Tetrahydronapthyridine and related analogs for inhibiting yap/taz-tead. The present disclosure re... |
|
|
Invention
|
Benzopiperazine and related analogs for inhibiting yap/taz-tead. The present disclosure relates t... |
|
|
Invention
|
Treatments with nirogacestat. The present disclosure relates to improved methods of treatment wit... |
|
|
Invention
|
Dosage forms of mirdametinib.
The present disclosure relates to an oral dosage form, such as a c... |
|
|
Invention
|
Improved treatment of ovarian cancer with nirogacestat.
The present disclosure relates to improv... |
|
|
Invention
|
Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylam... |
|
2023
|
Invention
|
Combination for use in treating cancers. The present disclosure relates to methods of treating ca... |
|
|
Invention
|
Non-linear dosing of mirdametinib. The present disclosure relates to methods for treating certain... |
|
|
Invention
|
Determination of bcma level on plasma cells by flow cytometry. Methods, systems, and computer rea... |
|
|
Invention
|
Treatment of multiple myeloma. The present disclosure provides methods of treating multiple myelo... |
|
|
Invention
|
Fluorinated phenylamino compounds and pharmaceutical compositions.
The present disclosure relate... |
|
|
Invention
|
Treatment of cutaneous neurofibromas with mirdametinib.
The present disclosure relates to method... |
|
|
Invention
|
Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead.
The present disclos... |
|
2022
|
Invention
|
Methods of treating multiple myeloma.
Provided herein are methods of treating multiple myeloma (... |
|
|
Invention
|
Chlorinated tetralin compounds and pharmaceutical compositions.
The present disclosures are dire... |
